- Home
- RLAY vs NXP Comparison
RLAY vs NXP Comparison
Compare RLAY & NXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- NXP
- Stock Information
- Founded
- RLAY 2015
- NXP 1992
- Country
- RLAY United States
- NXP United States
- Employees
- RLAY N/A
- NXP N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- NXP Trusts Except Educational Religious and Charitable
- Sector
- RLAY Health Care
- NXP Finance
- Exchange
- RLAY Nasdaq
- NXP Nasdaq
- Market Cap
- RLAY 803.4M
- NXP 741.7M
- IPO Year
- RLAY 2020
- NXP N/A
- Fundamental
- Price
- RLAY $6.72
- NXP $14.40
- Analyst Decision
- RLAY Strong Buy
- NXP
- Analyst Count
- RLAY 8
- NXP 0
- Target Price
- RLAY $17.25
- NXP N/A
- AVG Volume (30 Days)
- RLAY 2.0M
- NXP 70.0K
- Earning Date
- RLAY 11-06-2025
- NXP 01-01-0001
- Dividend Yield
- RLAY N/A
- NXP 4.04%
- EPS Growth
- RLAY N/A
- NXP N/A
- EPS
- RLAY N/A
- NXP 0.54
- Revenue
- RLAY $8,355,000.00
- NXP N/A
- Revenue This Year
- RLAY $27.30
- NXP N/A
- Revenue Next Year
- RLAY $7.43
- NXP N/A
- P/E Ratio
- RLAY N/A
- NXP $26.81
- Revenue Growth
- RLAY N/A
- NXP N/A
- 52 Week Low
- RLAY $1.78
- NXP $12.91
- 52 Week High
- RLAY $7.64
- NXP $14.89
- Technical
- Relative Strength Index (RSI)
- RLAY 55.13
- NXP 49.03
- Support Level
- RLAY $6.64
- NXP $14.26
- Resistance Level
- RLAY $7.42
- NXP $14.55
- Average True Range (ATR)
- RLAY 0.43
- NXP 0.12
- MACD
- RLAY -0.11
- NXP -0.02
- Stochastic Oscillator
- RLAY 30.97
- NXP 35.91
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About NXP Nuveen Select Tax Free Income Portfolio
Nuveen Select Tax Free Income Portfolio is a closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax, consistent with preservation of capital. The fund invests a majority of its assets in municipal securities and other related investments, the income from which is exempt from regular federal income tax and federal alternative minimum tax.